Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor cells in situ" is not a specific molecular target but rather a general term referring to cancerous or malignant cells located within their original tissue context. The phrase does not denote a single protein, receptor, enzyme, or other discrete molecular entity that can be directly targeted by drugs. Instead, it describes the presence of tumorigenic cells as they exist within the body—either as part of the primary tumor mass or detected through methods such as liquid biopsy (e.g., circulating tumor cells)[1]. While these cells are central to cancer biology and therapy development, "tumor cell in situ" is too broad and non-specific for use as a canonical therapeutic target. Molecular characterization of these cells can inform treatment decisions and disease monitoring but requires identification of specific actionable targets within them[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor cell in situ.